O	O	O	0	8	Cytokine	Cytokine	B-NP	NN	B-protein	0	ROOT	B-protein
O	O	O	8	9	-	-	O	HYPH	O	1	P	O
O	O	O	9	19	modulating	modulate	B-VP	VBG	O	1	NMOD	O
O	O	O	20	28	activity	activity	B-NP	NN	O	3	OBJ	O
O	O	O	29	31	of	of	B-PP	IN	O	4	NMOD	O
O	O	O	32	41	tepoxalin	tepoxalin	B-NP	NN	O	11	NMOD	O
O	O	O	41	42	,	,	O	,	O	11	P	O
O	O	O	43	44	a	a	B-NP	DT	O	11	NMOD	O
O	O	O	45	48	new	new	I-NP	JJ	O	10	AMOD	O
O	O	O	49	58	potential	potential	I-NP	NN	O	11	NMOD	O
O	O	O	59	72	antirheumatic	antirheumatic	B-ADJP	JJ	O	5	PMOD	O
O	O	O	72	73	.	.	O	.	O	1	P	O

O	O	O	75	84	Tepoxalin	Tepoxalin	B-NP	NN	O	2	SUB	O
O	O	O	85	87	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	88	89	a	a	B-NP	DT	O	10	NMOD	O
O	O	O	90	93	new	new	I-NP	JJ	O	10	NMOD	O
O	O	O	94	98	dual	dual	I-NP	JJ	O	10	NMOD	O
O	O	O	99	113	cyclooxygenase	cyclooxygenase	I-NP	NN	B-protein	10	NMOD	B-protein
O	O	O	113	114	/	/	B-NP	SYM	O	10	NMOD	O
O	O	O	114	115	5	5	I-NP	CD	O	10	NMOD	O
O	O	O	115	116	-	-	I-NP	HYPH	O	10	NMOD	O
O	O	O	116	128	lipoxygenase	lipoxygenase	I-NP	NN	B-protein	14	NMOD	B-protein
O	O	O	129	133	anti	anti	O	AFX	O	14	NMOD	O
O	O	O	133	134	-	-	O	HYPH	O	14	NMOD	O
O	O	O	134	146	inflammatory	inflammatory	B-NP	JJ	O	14	NMOD	O
O	O	O	147	155	compound	compound	I-NP	NN	O	2	PRD	O
O	O	O	156	165	currently	currently	B-ADVP	RB	O	16	PMOD	O
O	O	O	166	171	under	under	B-PP	IN	O	14	NMOD	O
O	O	O	172	180	clinical	clinical	B-NP	JJ	O	18	NMOD	O
O	O	O	181	194	investigation	investigation	I-NP	NN	O	16	PMOD	O
O	O	O	194	195	.	.	O	.	O	2	P	O

O	O	O	196	198	It	It	B-NP	PRP	O	2	SUB	O
O	O	O	199	202	has	have	B-VP	VBZ	O	0	ROOT	O
O	O	O	203	207	been	be	I-VP	VBN	O	2	VC	O
O	O	O	208	213	shown	show	I-VP	VBN	O	3	VC	O
O	O	O	214	216	to	to	I-VP	TO	O	6	VMOD	O
O	O	O	217	224	possess	possess	I-VP	VB	O	4	VMOD	O
O	O	O	225	229	anti	anti	B-NP	AFX	O	10	NMOD	O
O	O	O	229	230	-	-	I-NP	HYPH	O	10	NMOD	O
O	O	O	230	242	inflammatory	inflammatory	I-NP	JJ	O	10	NMOD	O
O	O	O	243	251	activity	activity	I-NP	NN	O	6	OBJ	O
O	O	O	252	254	in	in	B-PP	IN	O	6	VMOD	O
O	O	O	255	256	a	a	B-NP	DT	O	13	NMOD	O
O	O	O	257	264	variety	variety	I-NP	NN	O	11	PMOD	O
O	O	O	265	267	of	of	B-PP	IN	O	13	NMOD	O
O	O	O	268	274	animal	animal	B-NP	NN	O	16	NMOD	O
O	O	O	275	281	models	model	I-NP	NNS	O	14	PMOD	O
O	O	O	282	285	and	and	O	CC	O	6	VMOD	O
O	O	O	286	290	more	more	B-ADVP	RBR	O	19	AMOD	O
O	O	O	291	299	recently	recently	I-ADVP	RB	O	21	VMOD	O
O	O	O	300	302	to	to	B-VP	TO	O	21	VMOD	O
O	O	O	303	310	inhibit	inhibit	I-VP	VB	O	6	VMOD	O
T1	B-Protein	B-Protein	311	313	IL	IL	B-NP	NN	B-protein	27	NMOD	B-protein
T1	I-Protein	I-Protein	313	314	-	-	B-NP	HYPH	I-protein	22	NMOD	I-protein
T1	I-Protein	I-Protein	314	315	2	2	I-NP	CD	I-protein	22	NMOD	I-protein
O	O	O	316	323	induced	induce	B-VP	VBD	O	27	NMOD	O
O	O	O	324	330	signal	signal	B-NP	NN	O	27	NMOD	O
O	O	O	331	343	transduction	transduction	I-NP	NN	O	21	OBJ	O
O	O	O	343	344	.	.	O	.	O	2	P	O

O	O	O	345	348	The	The	B-NP	DT	O	3	NMOD	O
O	O	O	349	356	current	current	I-NP	JJ	O	3	NMOD	O
O	O	O	357	362	study	study	I-NP	NN	O	4	SUB	O
O	O	O	363	366	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	367	376	conducted	conduct	I-VP	VBN	O	4	VC	O
O	O	O	377	379	to	to	I-VP	TO	O	7	VMOD	O
O	O	O	380	388	evaluate	evaluate	I-VP	VB	O	4	VMOD	O
O	O	O	389	392	the	the	B-NP	DT	O	11	NMOD	O
O	O	O	393	401	cytokine	cytokine	I-NP	NN	B-protein	11	NMOD	B-protein
O	O	O	402	412	modulating	modulating	I-NP	NN	O	11	NMOD	O
O	O	O	413	421	activity	activity	I-NP	NN	O	16	NMOD	O
O	O	O	422	424	of	of	B-PP	IN	O	11	NMOD	O
O	O	O	425	434	tepoxalin	tepoxalin	B-NP	NN	O	12	PMOD	O
O	O	O	435	438	and	and	O	CC	O	16	NMOD	O
O	O	O	439	442	the	the	B-NP	DT	O	16	NMOD	O
O	O	O	443	447	role	role	I-NP	NN	O	7	OBJ	O
O	O	O	448	450	of	of	B-PP	IN	O	16	NMOD	O
O	O	O	451	455	iron	iron	B-NP	NN	O	17	PMOD	O
O	O	O	456	458	in	in	B-PP	IN	O	16	NMOD	O
O	O	O	459	464	these	these	B-NP	DT	O	21	NMOD	O
O	O	O	465	472	effects	effect	I-NP	NNS	O	19	PMOD	O
O	O	O	472	473	.	.	O	.	O	4	P	O

O	O	O	474	476	In	In	B-PP	IN	O	17	VMOD	O
O	O	O	477	482	human	human	B-NP	JJ	B-cell_type	6	NMOD	B-cell_type
O	O	O	483	493	peripheral	peripheral	I-NP	JJ	I-cell_type	6	NMOD	I-cell_type
O	O	O	494	499	blood	blood	I-NP	NN	I-cell_type	6	NMOD	I-cell_type
O	O	O	500	511	mononuclear	mononuclear	I-NP	JJ	I-cell_type	6	NMOD	I-cell_type
O	O	O	512	517	cells	cell	I-NP	NNS	I-cell_type	1	PMOD	I-cell_type
O	O	O	518	519	(	(	O	(	O	9	DEP	O
O	O	O	519	523	PBMC	PBMC	B-NP	NN	B-cell_type	9	DEP	B-cell_type
O	O	O	523	524	)	)	O	)	O	6	NMOD	O
O	O	O	525	535	stimulated	stimulate	B-VP	VBN	O	6	NMOD	O
O	O	O	536	540	with	with	B-PP	IN	O	10	VMOD	O
O	O	O	541	545	OKT3	OKT3	B-NP	NN	B-protein	14	NMOD	B-protein
O	O	O	545	546	/	/	I-NP	SYM	O	14	NMOD	O
O	O	O	546	549	PMA	PMA	I-NP	NN	O	11	PMOD	O
O	O	O	549	550	,	,	O	,	O	17	P	O
O	O	O	551	560	tepoxalin	tepoxalin	B-NP	NN	O	17	SUB	O
O	O	O	561	570	inhibited	inhibit	B-VP	VBD	O	0	ROOT	O
O	O	O	571	581	lymphocyte	lymphocyte	B-NP	NN	B-cell_type	19	NMOD	B-cell_type
O	O	O	582	595	proliferation	proliferation	I-NP	NN	O	17	OBJ	O
O	O	O	596	600	with	with	B-PP	IN	O	17	VMOD	O
O	O	O	601	603	an	an	B-NP	DT	O	22	NMOD	O
O	O	O	604	608	IC50	IC50	I-NP	NN	O	20	PMOD	O
O	O	O	609	611	of	of	B-PP	IN	O	22	NMOD	O
O	O	O	612	613	6	6	B-NP	CD	O	25	NMOD	O
O	O	O	614	620	microM	microM	I-NP	NN	O	23	PMOD	O
O	O	O	620	621	.	.	O	.	O	17	P	O

O	O	O	622	634	Additionally	Additionally	B-ADVP	RB	O	4	VMOD	O
O	O	O	634	635	,	,	O	,	O	4	P	O
O	O	O	636	638	it	it	B-NP	PRP	O	4	SUB	O
O	O	O	639	648	inhibited	inhibit	B-VP	VBD	O	0	ROOT	O
O	O	O	649	652	the	the	B-NP	DT	O	6	NMOD	O
O	O	O	653	663	production	production	I-NP	NN	O	4	OBJ	O
O	O	O	664	666	of	of	B-PP	IN	O	6	NMOD	O
T2	B-Protein	B-Protein	667	671	LTB4	LTB4	B-NP	NN	B-protein	19	NMOD	B-protein
O	O	O	672	673	(	(	O	(	O	16	DEP	O
O	O	O	673	677	IC50	IC50	B-NP	NN	O	16	DEP	O
O	O	O	678	679	=	=	B-VP	SYM	O	10	NMOD	O
O	O	O	680	681	0	0	B-NP	CD	O	14	AMOD	O
O	O	O	681	682	.	.	I-NP	SYM	O	14	AMOD	O
O	O	O	682	683	5	5	I-NP	CD	O	15	NMOD	O
O	O	O	684	690	microM	microM	I-NP	NN	O	11	AMOD	O
O	O	O	690	691	)	)	O	)	O	8	NMOD	O
O	O	O	692	695	and	and	O	CC	O	19	NMOD	O
O	O	O	696	699	the	the	B-NP	DT	O	19	NMOD	O
O	O	O	700	709	cytokines	cytokine	I-NP	NNS	B-protein	21	NMOD	B-protein
T3	B-Protein	B-Protein	710	712	IL	IL	I-NP	NN	B-protein	21	NMOD	B-protein
T3	I-Protein	I-Protein	712	713	-	-	B-NP	HYPH	I-protein	29	NMOD	I-protein
T3	I-Protein	I-Protein	713	714	2	2	I-NP	CD	I-protein	21	NMOD	I-protein
O	O	O	714	715	,	,	O	,	O	21	P	O
T4	B-Protein	B-Protein	716	718	IL	IL	B-NP	NN	B-protein	29	NMOD	B-protein
T4	I-Protein	I-Protein	718	719	-	-	O	HYPH	I-protein	29	P	I-protein
T4	I-Protein	I-Protein	719	720	6	6	B-NP	CD	I-protein	29	NMOD	I-protein
O	O	O	721	724	and	and	O	CC	O	29	NMOD	O
T5	B-Protein	B-Protein	725	728	TNF	TNF	B-NP	NN	B-protein	29	NMOD	B-protein
T5	I-Protein	I-Protein	729	734	alpha	alpha	B-NP	SYM	I-protein	7	PMOD	I-protein
O	O	O	735	736	(	(	O	(	O	37	DEP	O
O	O	O	736	740	IC50	IC50	B-NP	NN	O	37	DEP	O
O	O	O	741	742	=	=	B-VP	SYM	O	31	NMOD	O
O	O	O	743	745	10	10	B-NP	CD	O	36	NMOD	O
O	O	O	745	746	-	-	I-NP	HYPH	O	36	NMOD	O
O	O	O	746	748	12	12	I-NP	CD	O	36	NMOD	O
O	O	O	749	755	microM	microM	I-NP	NN	O	32	AMOD	O
O	O	O	755	756	)	)	O	)	O	29	NMOD	O
O	O	O	756	757	.	.	O	.	O	4	P	O

O	O	O	758	770	Cytotoxicity	Cytotoxicity	B-NP	NN	O	2	SUB	O
O	O	O	771	774	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	775	778	not	not	I-VP	RB	O	2	VMOD	O
O	O	O	779	791	demonstrated	demonstrate	I-VP	VBN	O	2	VC	O
O	O	O	792	794	at	at	B-PP	IN	O	4	VMOD	O
O	O	O	795	800	these	these	B-NP	DT	O	7	NMOD	O
O	O	O	801	815	concentrations	concentration	I-NP	NNS	O	5	PMOD	O
O	O	O	815	816	.	.	O	.	O	2	P	O

O	O	O	817	820	Add	Add	B-NP	NN	B-protein	4	NMOD	B-protein
O	O	O	820	821	-	-	B-VP	HYPH	O	4	VMOD	O
O	O	O	821	825	back	back	B-PRT	RP	O	2	VMOD	O
O	O	O	826	837	experiments	experiment	B-NP	NNS	O	22	SUB	O
O	O	O	838	842	with	with	B-PP	IN	O	4	NMOD	O
O	O	O	843	849	either	either	O	CC	O	21	NMOD	O
O	O	O	850	859	cytokines	cytokine	B-NP	NNS	B-protein	21	NMOD	B-protein
O	O	O	860	861	(	(	O	(	O	16	DEP	O
T6	B-Protein	B-Protein	861	863	IL	IL	B-NP	NN	B-protein	14	NMOD	B-protein
T6	I-Protein	I-Protein	863	864	-	-	B-NP	HYPH	I-protein	9	NMOD	I-protein
T6	I-Protein	I-Protein	864	865	2	2	I-NP	CD	I-protein	9	NMOD	I-protein
O	O	O	866	868	or	or	I-NP	CC	O	14	NMOD	O
T7	B-Protein	B-Protein	869	871	IL	IL	I-NP	NN	B-protein	14	NMOD	B-protein
T7	I-Protein	I-Protein	871	872	-	-	O	HYPH	I-protein	16	DEP	I-protein
T7	I-Protein	I-Protein	872	873	6	6	B-NP	CD	I-protein	14	NMOD	I-protein
O	O	O	873	874	)	)	O	)	O	7	NMOD	O
O	O	O	874	875	,	,	O	,	O	21	P	O
T8	B-Protein	B-Protein	876	880	LTB4	LTB4	B-NP	NN	B-protein	21	NMOD	B-protein
O	O	O	881	883	or	or	O	CC	O	21	NMOD	O
O	O	O	884	895	conditioned	condition	B-NP	VBN	O	21	NMOD	O
O	O	O	896	901	media	medium	I-NP	NNS	O	5	PMOD	O
O	O	O	902	908	failed	fail	B-VP	VBD	O	0	ROOT	O
O	O	O	909	911	to	to	I-VP	TO	O	24	VMOD	O
O	O	O	912	919	restore	restore	I-VP	VB	O	22	VMOD	O
O	O	O	920	923	the	the	B-NP	DT	O	27	NMOD	O
O	O	O	924	937	proliferative	proliferative	I-NP	JJ	O	27	NMOD	O
O	O	O	938	946	response	response	I-NP	NN	O	24	OBJ	O
O	O	O	947	949	in	in	B-PP	IN	O	24	VMOD	O
O	O	O	950	953	the	the	I-PP	DT	O	30	NMOD	O
O	O	O	954	962	presence	presence	I-PP	NN	O	28	PMOD	O
O	O	O	963	965	of	of	I-PP	IN	O	30	NMOD	O
O	O	O	966	975	tepoxalin	tepoxalin	B-NP	NN	O	31	PMOD	O
O	O	O	975	976	.	.	O	.	O	22	P	O

O	O	O	977	984	However	However	B-ADVP	RB	O	22	VMOD	O
O	O	O	984	985	,	,	O	,	O	22	P	O
O	O	O	986	989	the	the	B-NP	DT	O	5	NMOD	O
O	O	O	990	1000	concurrent	concurrent	I-NP	JJ	O	5	NMOD	O
O	O	O	1001	1009	addition	addition	I-NP	NN	O	22	SUB	O
O	O	O	1010	1012	of	of	B-PP	IN	O	5	NMOD	O
O	O	O	1013	1017	iron	iron	B-NP	NN	O	6	PMOD	O
O	O	O	1018	1019	(	(	O	(	O	21	DEP	O
O	O	O	1019	1021	in	in	B-PP	IN	O	21	DEP	O
O	O	O	1022	1025	the	the	B-NP	DT	O	11	NMOD	O
O	O	O	1026	1030	form	form	I-NP	NN	O	9	PMOD	O
O	O	O	1031	1033	of	of	B-PP	IN	O	11	NMOD	O
O	O	O	1034	1041	ferrous	ferrous	B-NP	JJ	O	16	NMOD	O
O	O	O	1042	1044	or	or	I-NP	CC	O	16	NMOD	O
O	O	O	1045	1051	ferric	ferric	I-NP	JJ	O	16	NMOD	O
O	O	O	1052	1060	chloride	chloride	I-NP	NN	O	20	NMOD	O
O	O	O	1061	1064	and	and	O	CC	O	20	NMOD	O
O	O	O	1065	1070	other	other	B-NP	JJ	O	20	NMOD	O
O	O	O	1071	1075	iron	iron	I-NP	NN	O	20	NMOD	O
O	O	O	1076	1081	salts	salt	I-NP	NNS	O	12	PMOD	O
O	O	O	1081	1082	)	)	O	)	O	7	NMOD	O
O	O	O	1083	1091	reversed	reverse	B-VP	VBD	O	0	ROOT	O
O	O	O	1092	1095	the	the	B-NP	DT	O	24	NMOD	O
O	O	O	1096	1106	inhibition	inhibition	I-NP	NN	O	22	OBJ	O
O	O	O	1107	1109	of	of	B-PP	IN	O	24	NMOD	O
O	O	O	1110	1123	proliferation	proliferation	B-NP	NN	O	25	PMOD	O
O	O	O	1124	1130	caused	cause	B-VP	VBN	O	24	NMOD	O
O	O	O	1131	1133	by	by	B-PP	IN	O	27	VMOD	O
O	O	O	1134	1143	tepoxalin	tepoxalin	B-NP	NN	O	28	PMOD	O
O	O	O	1143	1144	.	.	O	.	O	22	P	O

O	O	O	1145	1154	Tepoxalin	Tepoxalin	B-NP	NN	O	3	SUB	O
O	O	O	1155	1159	also	also	B-ADVP	RB	O	3	VMOD	O
O	O	O	1160	1168	inhibits	inhibit	B-VP	VBZ	O	0	ROOT	O
O	O	O	1169	1172	the	the	B-NP	DT	O	5	NMOD	O
O	O	O	1173	1183	activation	activation	I-NP	NN	O	3	OBJ	O
O	O	O	1184	1186	of	of	B-PP	IN	O	5	NMOD	O
T9	B-Entity	B-Entity	1187	1189	NF	NF	B-NP	NN	B-protein	9	NMOD	B-protein
T9	I-Entity	I-Entity	1190	1195	kappa	kappa	I-NP	NN	I-protein	9	NMOD	I-protein
T9	I-Entity	I-Entity	1196	1197	B	B	I-NP	NN	I-protein	13	NMOD	I-protein
O	O	O	1197	1198	,	,	O	,	O	13	P	O
O	O	O	1199	1200	a	a	B-NP	DT	O	13	NMOD	O
O	O	O	1201	1214	transcription	transcription	I-NP	NN	B-protein	13	NMOD	B-protein
O	O	O	1215	1221	factor	factor	I-NP	NN	I-protein	6	PMOD	I-protein
O	O	O	1222	1227	which	which	B-NP	WDT	O	13	NMOD	O
O	O	O	1228	1232	acts	act	B-VP	VBZ	O	14	SBAR	O
O	O	O	1233	1235	on	on	B-PP	IN	O	15	VMOD	O
O	O	O	1236	1243	several	several	B-NP	JJ	O	19	NMOD	O
T10	B-Entity	B-Entity	1244	1252	cytokine	cytokine	I-NP	NN	B-DNA	19	NMOD	B-DNA
T10	I-Entity	I-Entity	1253	1258	genes	gene	I-NP	NNS	I-DNA	16	PMOD	I-DNA
O	O	O	1258	1259	.	.	O	.	O	3	P	O

O	O	O	1260	1269	Tepoxalin	Tepoxalin	B-NP	NN	O	4	NMOD	O
O	O	O	1269	1270	'	'	B-NP	POS	O	4	NMOD	O
O	O	O	1270	1271	s	s	I-NP	NN	O	4	NMOD	O
O	O	O	1272	1278	effect	effect	I-NP	NN	O	9	SUB	O
O	O	O	1279	1281	on	on	B-PP	IN	O	4	NMOD	O
T11	B-Entity	B-Entity	1282	1284	NF	NF	B-NP	NN	B-protein	8	NMOD	B-protein
T11	I-Entity	I-Entity	1285	1290	kappa	kappa	I-NP	NN	I-protein	8	NMOD	I-protein
T11	I-Entity	I-Entity	1291	1292	B	B	I-NP	NN	I-protein	5	PMOD	I-protein
O	O	O	1293	1295	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	1296	1300	also	also	I-VP	RB	O	9	VMOD	O
O	O	O	1301	1309	reversed	reverse	I-VP	VBN	O	9	VC	O
O	O	O	1310	1312	by	by	B-PP	IN	O	11	VMOD	O
O	O	O	1313	1316	the	the	B-NP	DT	O	14	NMOD	O
O	O	O	1317	1325	addition	addition	I-NP	NN	O	12	PMOD	O
O	O	O	1326	1328	of	of	B-PP	IN	O	14	NMOD	O
O	O	O	1329	1333	iron	iron	B-NP	NN	O	17	NMOD	O
O	O	O	1334	1339	salts	salt	I-NP	NNS	O	15	PMOD	O
O	O	O	1339	1340	.	.	O	.	O	9	P	O

O	O	O	1341	1346	These	These	B-NP	DT	O	2	NMOD	O
O	O	O	1347	1351	data	datum	I-NP	NNS	O	3	SUB	O
O	O	O	1352	1359	suggest	suggest	B-VP	VBP	O	0	ROOT	O
O	O	O	1360	1364	that	that	B-SBAR	IN	O	3	VMOD	O
O	O	O	1365	1368	the	the	B-NP	DT	O	6	NMOD	O
O	O	O	1369	1375	action	action	I-NP	NN	O	14	SUB	O
O	O	O	1376	1378	of	of	B-PP	IN	O	6	NMOD	O
O	O	O	1379	1388	tepoxalin	tepoxalin	B-NP	NN	O	7	PMOD	O
O	O	O	1389	1391	to	to	B-VP	TO	O	10	VMOD	O
O	O	O	1392	1399	inhibit	inhibit	I-VP	VB	O	6	NMOD	O
O	O	O	1400	1413	proliferation	proliferation	B-NP	NN	O	10	OBJ	O
O	O	O	1414	1416	in	in	B-PP	IN	O	10	VMOD	O
O	O	O	1417	1421	PBMC	PBMC	B-NP	NN	B-cell_type	12	PMOD	B-cell_type
O	O	O	1422	1425	may	may	B-VP	MD	O	4	SBAR	O
O	O	O	1426	1428	be	be	I-VP	VB	O	14	VC	O
O	O	O	1429	1431	at	at	B-ADVP	IN	O	18	PMOD	O
O	O	O	1432	1437	least	least	I-ADVP	JJS	O	16	AMOD	O
O	O	O	1438	1440	in	in	B-PP	IN	O	15	VMOD	O
O	O	O	1441	1445	part	part	B-NP	NN	O	18	PMOD	O
O	O	O	1446	1449	due	due	B-PP	JJ	O	15	PRD	O
O	O	O	1450	1452	to	to	B-PP	TO	O	20	AMOD	O
O	O	O	1453	1456	its	its	B-NP	PRP$	O	23	NMOD	O
O	O	O	1457	1464	ability	ability	I-NP	NN	O	21	PMOD	O
O	O	O	1465	1467	to	to	B-VP	TO	O	25	VMOD	O
O	O	O	1468	1474	reduce	reduce	I-VP	VB	O	23	NMOD	O
O	O	O	1475	1478	the	the	B-NP	DT	O	27	NMOD	O
O	O	O	1479	1485	amount	amount	I-NP	NN	O	25	OBJ	O
O	O	O	1486	1488	of	of	B-PP	IN	O	27	NMOD	O
O	O	O	1489	1498	available	available	B-NP	JJ	O	30	NMOD	O
O	O	O	1499	1503	iron	iron	I-NP	NN	O	28	PMOD	O
O	O	O	1504	1513	resulting	result	B-VP	VBG	O	23	NMOD	O
O	O	O	1514	1516	in	in	B-PP	IN	O	31	VMOD	O
O	O	O	1517	1526	decreased	decrease	B-NP	VBN	O	34	NMOD	O
O	O	O	1527	1537	activation	activation	I-NP	NN	O	41	NMOD	O
O	O	O	1538	1540	of	of	B-PP	IN	O	34	NMOD	O
T12	B-Entity	B-Entity	1541	1543	NF	NF	B-NP	NN	B-protein	38	NMOD	B-protein
T12	I-Entity	I-Entity	1544	1549	kappa	kappa	I-NP	NN	I-protein	38	NMOD	I-protein
T12	I-Entity	I-Entity	1550	1551	B	B	I-NP	NN	I-protein	35	PMOD	I-protein
O	O	O	1552	1555	and	and	O	CC	O	41	NMOD	O
O	O	O	1556	1566	subsequent	subsequent	B-NP	JJ	O	41	NMOD	O
O	O	O	1567	1577	inhibition	inhibition	I-NP	NN	O	32	PMOD	O
O	O	O	1578	1580	of	of	B-PP	IN	O	41	NMOD	O
O	O	O	1581	1589	cytokine	cytokine	B-NP	NN	B-protein	44	NMOD	B-protein
O	O	O	1590	1600	production	production	I-NP	NN	O	42	PMOD	O
O	O	O	1600	1601	.	.	O	.	O	3	P	O
